Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4 Other hematologic neoplasm 3 Tumor-Agnostic 2 Myeloid 2 Lymphoid 1 Gastrointestinal 1

Conditions

Hodgkin Disease 1

Interventions

Rituximab 1371 Cyclophosphamide 1297 Vincristine 662 Doxorubicin 583 Etoposide 525 Prednisone 504 Cytarabine 481 fludarabine 462 Methotrexate 441 Dexamethasone 411 fludarabine phosphate 396 Lenalidomide 347 Filgrastim 342 Bendamustine Hydrochloride 274 Radiotherapy 266 venetoclax 255 ibrutinib 249 Peripheral Blood Stem Cell Transplantation 233 Melphalan 229 obinutuzumab 228 Granulocyte Colony-Stimulating Factor 212 Bortezomib 204 Gemcitabine 201 Busulfan 186 Whole-Body Irradiation 185 Mycophenolic Acid 174 Tacrolimus 164 Specimen Handling 161 Calcium Dobesilate 150 Magnetic Resonance Spectroscopy 149

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × axatilimab × Lymphoid × Clear all

NCT05723055 2026-05-08

NAHL

University of Utah

Phase 2 Active not recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡